MEWIGEN offers the NGS-based detection of somatic markers from blood plasma samples. This enables the sampling of information for further therapy planning in a non-invasive way.
Gene
Mutations
Exons
EGFR
activating mutations
18 – 21
NM_005228.5
c.2062-2625, p.688-875
PIK3CA
activating mutations
8, 10 and 21
NM_006218.4
c.1252-1404, p.419-469 (E8)
c.1540-1664, p.514-555 (E10)
c.2937-3207, p.979-* (E21)
PIK3CA
E542K, E545K, H1047R/L
Targeted examination
NM_006218.4
c.1624G>A
NM_006218.4
c.1633G>A
NM_006218.4
c.3140A>G / c.3140A>T
Method:
NGS
Turnaround time:
6 weeks
Specimen requirements:
10 ml blood sample collected in cfDNA stabilizing tubes like Streck or PaxGene tubes